MyFinsight
Home
Blog
About
Total revenues
$989,708K
(19.91%↑ Y/Y)
Proceeds from borrowings
$2,800,000K
Depreciation and
amortization
$97,638K
(425.98%↑ Y/Y)
Stock-based compensation
$75,694K
(59.25%↑ Y/Y)
Proceeds from exercises
of awards under...
$6,655K
(-13.65%↓ Y/Y)
Net income
$44,762K
(-81.39%↓ Y/Y)
Accounts payable and
accrued liabilities
$23,165K
(301.75%↑ Y/Y)
Non-cash interest
expense
$21,826K
(3206.97%↑ Y/Y)
Other assets
-$7,521K
(-163.30%↓ Y/Y)
Canceled cashflow
$944,946K
Net cash provided by
(used in) financing...
$2,738,380K
(59591.20%↑ Y/Y)
Net cash provided by
operating activities
$168,109K
(-9.26%↓ Y/Y)
Canceled cashflow
$68,275K
Canceled cashflow
$102,952K
G&a expenses
$253,363K
(129.96%↑ Y/Y)
Cost of sales
$202,795K
(35.12%↑ Y/Y)
S&m expenses
$142,186K
(16.45%↑ Y/Y)
Other segment
expense, net
$139,650K
(238.95%↑ Y/Y)
R&d
expenses-Research And Early...
$85,069K
(-11.36%↓ Y/Y)
R&d
expenses-Marketed Products
$71,588K
(37.12%↑ Y/Y)
R&d expenses-Later
Stage Clinical...
$50,295K
(282.97%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$2,198,430K
(-1432.28%↓ Y/Y)
Canceled cashflow
$2,906,489K
Payments of debt issuance
costs
$56,951K
Taxes paid related to
net share...
$11,324K
(-8.01%↓ Y/Y)
Accounts receivable, net
$38,846K
(-60.58%↓ Y/Y)
Inventory
$32,156K
(-33.19%↓ Y/Y)
Other current assets
$12,038K
(37.34%↑ Y/Y)
Unrealized foreign
exchange gains
$10,756K
(327.88%↑ Y/Y)
Deferred income taxes
-$6,959K
(-120.87%↓ Y/Y)
Other long-term
liabilities
-$2,037K
(-158.74%↓ Y/Y)
Other
$160K
(-75.35%↓ Y/Y)
Net cash used in
investing activities
-$5,101,879K
(-40416.83%↓ Y/Y)
Effect of exchange rate
changes on cash
-$3,040K
(0.75%↑ Y/Y)
Acquisition of amicus, net of
cash acquired
$5,067,630K
Purchases of property,
plant and equipment
$28,816K
(68.50%↑ Y/Y)
Purchase of intangible
assets
$5,433K
(1942.48%↑ Y/Y)
Back
Back
Cash Flow
biomarin-logo-svg
source: myfinsight.com
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)